Statement: in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin
Primary_evidence: Outcome Measurement:    Number of Participants With Disease Progression (PD) or Death   This endpoint evaluated the progression free survival (PFS) of participants amongst the total evaluable population. Progression free survival (PFS) was defined as the time from randomization to either the date the subject was first recorded as having PD (even if the subject went off treatment because of toxicity), or the date of death if the subject died due to any causes before progression. Participants with no recorded post-baseline tumor assessment had PFS censored at the day of randomization. Participants lost to follow-up were censored at the last date of contact. Participants that had not progressed or died had PFS censored at the date of last follow-up.   Time frame: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years) Results 1:    Arm/Group Title: Fulvestrant and Dasatinib   Arm/Group Description: Arm 1: Participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib.   Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years.   Dasatinib: Tablets, Oral, 100 mg, once daily (QD), up to 2 years   Overall Number of Participants Analyzed: 50   Measure Type: Number   Unit of Measure: participants  35 Results 2:    Arm/Group Title: Fulvestrant   Arm/Group Description: Arm 2: Participants in this group received a drug regimen that consisted of fulvestrant only.   Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years.   Overall Number of Participants Analyzed: 49   Measure Type: Number   Unit of Measure: participants  40